Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and efficacy. METHODS: We conducted a randomized trial involving 2341 patients at high risk for cardiovascular events who had LDL cholesterol levels of 70 mg per deciliter (1.8 mmol per liter) or more and were receiving treatment with statins at the maximum tolerated dose (the highest dose associated with an acceptable side-effect profile), with or without other lipid-lowering therapy. Patients were randomly assigned in a 2:1 ratio to receive alirocumab (150 mg) or placebo as a 1-ml subcutaneous injection every 2 weeks for 78 weeks. The primary efficacy end point was the percentage change in calculated LDL cholesterol level from baseline to week 24. RESULTS: At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL cholesterol level was -62 percentage points (P<0.001); the treatment effect remained consistent over a period of 78 weeks. The alirocumab group, as compared with the placebo group, had higher rates of injection-site reactions (5.9% vs. 4.2%), myalgia (5.4% vs. 2.9%), neurocognitive events (1.2% vs. 0.5%), and ophthalmologic events (2.9% vs. 1.9%). In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization) was lower with alirocumab than with placebo (1.7% vs. 3.3%; hazard ratio, 0.52; 95% confidence interval, 0.31 to 0.90; nominal P=0.02). CONCLUSIONS: Over a period of 78 weeks, alirocumab, when added to statin therapy at the maximum tolerated dose, significantly reduced LDL cholesterol levels. In a post hoc analysis, there was evidence of a reduction in the rate of cardiovascular events with alirocumab. (Funded by Sanofi and Regeneron Pharmaceuticals; ODYSSEY LONG TERM ClinicalTrials.gov number, NCT01507831.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The efficacy at reducing LDL-C is in the range of 50-70%, independent of the presence of a background therapy (statins, ezetimibe, etc.); preliminary data from phase 3 trials suggest a reduction of CV events in line with the LDL-C reduction achieved.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the initial trials of these drugs, the incidence of neurocognitive adverse events (including delirium, cognitive and attentional disturbances, dementia, thought and perceptual disturbances, and psychiatric disorders) was very low (<1%) but slightly higher albeit non-significantly in the treated groups compared with placebo (0.9% vs. 0.3% for evolocumab) (81) (1.2% vs. 0.5% for alirocumab) (82).”
From PCSK9 and the nervous system: a no-brainer? (2023) · cites this paper as [81]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“alirocumab, a PCSK9 monoclonal antibody in clinical use (Robinson et al., 2015)”
From γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor (2018) · cites this paper as Robinson et al., 2015
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Data from the GLAGOV, ODYSSEY COMBO I and ODYSSEY LONG TERM trials show greater efficacy of PCSK9 inhibitors in patients with prior CVD (or myocardial infarction) in terms of LDL-C and percent atheroma volume [86–88].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [88]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [270]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437738.63853.7a · Cited by 7,081
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
ESC/EAS Guidelines for the management of dyslipidaemias
Reiner, Ž., Catapano, A. L., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr158 · Cited by 3,549
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Self-citationNiacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911
Effects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Cited by
Items 701–800 of 1,019
Taskinen, M., Björnson, E., Andersson, L. K., Kahri, J., Porthan, K., Matikainen, N., Söderlund, S., Pietiläinen, K. H., Hakkarainen, A., Lundbom, N. M. I., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.12.003 · Cited by 33
Farnier, M., Colhoun, H. M., Sasiela, W. J., Edelberg, J. M., Asset, G., & Robinson, J. G. (2017) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2017.05.016 · Cited by 30
Self-citationPCSK9 inhibition and atherosclerotic cardiovascular disease prevention: does reality match the hype?
Hadjiphilippou, S., & Ray, K. K. (2017) · Heart · doi:10.1136/heartjnl-2016-310844 · Cited by 31
Lipoprotein(a): new insights from modern genomics
Afshar, M. S., & Thanassoulis, G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000392 · Cited by 30
Novel lipid modifying drugs to lower LDL cholesterol
Cupido, A. J., Reeskamp, L. F., & Kastelein, J. J. P. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000428 · Cited by 30
Self-citationMüller‐Wieland, D., Leiter, L. A., Cariou, B., Letierce, A., Colhoun, H. M., Prato, S. D., Henry, R. R., Tinahones, F. J., Aurand, L. A., Maroni, J. M., et al. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0552-4 · Cited by 30
“Data from a post hoc analysis of the ODYSSEY LONG TERM trial have been promising, with early indication of a reduced rate of cardiovascular events with alirocumab [28].”
MethodHistory of lipidology and lipoprotein apheresis
Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.034 · Cited by 32
Treatment of Cholesterol in 2017
Krumholz, H. M. (2017) · JAMA · doi:10.1001/jama.2017.6753 · Cited by 30
Vallejo‐Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Eckel, R. H., Cannon, C. P., Lee, L. V., Bessac, L., Pordy, R. C., Letierce, A., & Ray, K. K. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009221 · Cited by 30
Self-citationGonna, H., & Ray, K. K. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13691 · Cited by 33
Mendelian randomization studies on atherosclerotic cardiovascular disease: evidence and limitations
Hu, Q., Hao, P., Liu, Q., Dong, M., Gong, Y., Zhang, C., & Zhang, Y. (2019) · Science China Life Sciences · doi:10.1007/s11427-019-9537-4 · Cited by 32
Farrah, T. E., Anand, A., Gallacher, P. J., Kimmitt, R. A., Carter, E., Dear, J. W., Mills, N. L., Webb, D. J., & Dhaun, N. (2019) · Hypertension · doi:10.1161/hypertensionaha.119.12919 · Cited by 30
Zhang, Z., Wei, T., Zhao, B., Yin, Z. F., Shi, Q., Liu, P., Liu, L., Liu, L., Zhao, J., Mao, S., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-35773-x · Cited by 30
Environmentally responsive hydrogels for repair of cardiovascular tissue
Guan, S., Li, J., Zhang, K., & Li, J. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09934-y · Cited by 30
Proprotein Convertase Subtilisin/Kexin-Type 9 and Lipid Metabolism
Guo, S., Xia, X.-D., Gu, H.-M., & Zhang, D. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-981-15-6082-8_9 · Cited by 36
Exploiting nanoscale cooperativity for precision medicine
Wilhelm, J., Wang, Z., Sumer, B. D., & Gao, J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.08.012 · Cited by 30
Khan, S. U., Khan, M. U., Virani, S. S., Khan, M. S., Khan, M. Z., Rashid, M. O., Kalra, A., Alkhouli, M. A., Blaha, M. J., Blumenthal, R. S., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa093 · Cited by 34
Discovery of Novel Small Molecule Inhibitors Disrupting the PCSK9-LDLR Interaction
Sun, H., Wang, J., Liu, S., Zhou, X., Dai, L. X., Chen, C., Xu, Q., Wen, X., Cheng, K., Sun, H., et al. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00521 · Cited by 30
Vicente-Valor, J., García‐González, X., Ibáñez-García, S., Durán-García, M. E., de Lorenzo‐Pinto, A., Rodríguez, C., Méndez, I., Percovich-Hualpa, J. C., Alonso, A. H., & Sanjurjo‐Sáez, M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112519 · Cited by 30
Puri, R., Mehta, V., Duell, P. B., Wangnoo, S. K., Rastogi, A., Mohan, V., Zargar, A. H., Kalra, S., Sahoo, A., Iyengar, S. S., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.11.002 · Cited by 34
Medical Management of Dyslipidemia for Secondary Stroke Prevention: Narrative Review
Chang, Y., Eom, S., Kim, M.-J., & Song, T. (2023) · Medicina · doi:10.3390/medicina59040776 · Cited by 31
Huo, Y., Chen, B., Lian, Q., Wang, S., Liu, L., Lu, D., Qu, Y., Zheng, G., Li, L., Ji, Y., et al. (2023) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2023.100907 · Cited by 36
Simons, N., Dekker, J. M., van Greevenbroek, M. M. J., Nijpels, G., Hart, L. M. ‘., Kallen, C., Schalkwijk, C. G., Schaper, N. C., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2016) · Diabetes Care · doi:10.2337/dc16-0153 · Cited by 30
Plaque imaging to refine indications for emerging lipid-lowering drugs
Alkhalil, M., Chai, J. T., & Choudhury, R. P. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw034 · Cited by 33
“using evolocumab or alirocumab, leads to marked LDL-c reduction.(19,20,23) In fact, both drugs are very effective in reducing plasma LDL-c level (by approximately 60% when added to statins).”
BackgroundMethodDesai, N. R., Giugliano, R. P., Wasserman, S. M., Gibbs, J. P., Liu, T., Scott, R. C., & Sabatine, M. S. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2016.5395 · Cited by 30
Bays, H. E., Rosenson, R. S., Baccara‐Dinet, M. T., Louie, M. J., Thompson, D. E., & Hovingh, G. K. (2018) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-018-6784-z · Cited by 31
“Patient blood samples for lipid analysis were taken under fasting conditions and were assayed by central laboratories (Medpace Reference Laboratories, Cincinnati, OH, and Leuven, Belgium, except for the LONG TERM study [12], which used Covance Central Laboratories, Indianapolis, IN, and Geneva, Switzerland).”
MethodFurtado, R. H. M., & Giugliano, R. P. (2020) · Cardiology and Therapy · doi:10.1007/s40119-020-00163-w · Cited by 34
“In prior randomized trials designed for LDLC lowering, both evolocumab and alirocumab demonstrated a possible signal for higher rates of adverse events related to cognitive impairment [37, 38].”
BackgroundHeo, K., Phan, L. P., Le, N. T. T., & Jin, Y. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01542-4 · Cited by 35
Lipid-Lowering Drug Therapy for CVD Prevention: Looking into the Future
Stein, E. A., & Raal, F. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0659-8 · Cited by 29
Self-citationNew developments in atherosclerosis: clinical potential of PCSK9 inhibition
Tavori, H., & Giunzioni, I. (2015) · Vascular Health and Risk Management · doi:10.2147/vhrm.s74692 · Cited by 34
Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes
Turner, T. A., & Stein, E. A. (2015) · Clinical Therapeutics · doi:10.1016/j.clinthera.2015.09.004 · Cited by 31
“Alirocumab and evolocumab were well tolerated in the Phase II trials that were of 8 to 12 weeks in duration, and concern remained as to longer term adherence, given that this was the first mainstream subcutaneous therapy for LDL-C.”
BackgroundResultInfluentialStein, E. A., & Raal, F. J. (2016) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-016-6654-5 · Cited by 29
Self-citationChackerian, B., & Remaley, A. T. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000312 · Cited by 29
Thyroid hormone analogs for the treatment of dyslipidemia: past, present, and future
Delitala, A. P., Delitala, G., Sioni, P., & Fanciulli, G. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1330259 · Cited by 29
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR
Safarova, M. S., Satterfield, B. A., Fan, X., Austin, E. E., Ye, Z., Bastarache, L. A., Zheng, N. S., Ritchie, M. D., Borthwick, K. M., Williams, M. S., et al. (2019) · npj Genomic Medicine · doi:10.1038/s41525-019-0078-7 · Cited by 32
Natarajan, P., & Kathiresan, S. (2016) · Cell · doi:10.1016/j.cell.2016.05.016 · Cited by 29
Estimation of the major cardiovascular events prevention with Inclisiran
Cordero, A., Santos‐Gallego, C. G., Fácila, L., Rodríguez‐Mañero, M., Bertomeu‐González, V., Castellano, J. M., Seijas‐Amigo, J., Núñez, J. E., Zuazola, P., González‐Juanatey, J. R., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.09.021 · Cited by 32
Elbitar, S., Khoury, P. E., Ghaleb, Y., Rabès, J., Varret, M., Seidah, N. G., Boileau, C., & Abifadel, M. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2016.1206080 · Cited by 29
“At week 24, the difference between the alirocumab and placebo groups in the mean percentage change from baseline in calculated LDL-C level was −62%; the treatment effect remained consistent over a period of 78 weeks [83].”
MethodNowak, C., Salihović, S., Ganna, A., Brandmaier, S., Tukiainen, T., Broeckling, C. D., Magnusson, P. K. E., Prenni, J. E., Wang‐Sattler, R., Peters, A., et al. (2016) · PLoS Genetics · doi:10.1371/journal.pgen.1006379 · Cited by 29
Djebli, N., Martinez, J.-M., Lohan, L., Khier, S., Brunet, A., Hurbin, F., & Fabre, D. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0505-1 · Cited by 30
“Subsequently, the model was expanded to a larger data set (2870 subjects/patients from 13 studies) [15, 16, 18, 19, 24].”
MethodHohenstein, B., Julius, U., Lansberg, P. J., Jaeger, B. R., Mellwig, K., Weiss, N., Graehlert, X., Roeder, I., & Ramlow, W. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.009 · Cited by 29
Targeting PCSK9 as a promising new mechanism for lowering low-density lipoprotein cholesterol
Badia, L. A. D., Elshourbagy, N. A., & Mousa, S. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.04.011 · Cited by 29
G-Protein Coupled Receptor Targeting on Myeloid Cells in Atherosclerosis
van der Vorst, E. P. C., Peters, L. J. F., Müller, M., Gencer, S., Yan, Y., Weber, C., & Döring, Y. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00531 · Cited by 30
PCSK9 Inhibitors: A Technology Worth Paying For?
Weintraub, W. S., & Gidding, S. S. (2015) · PharmacoEconomics · doi:10.1007/s40273-015-0355-y · Cited by 29
“complementary fashion, with resultant dramatic lowering of LDL-C, in the presence of these other therapies [2, 3].”
BackgroundRecent advances in anti-inflammatory active components and action mechanisms of natural medicines
Wu, Z., Zhang, T., Ma, X., Guo, S., Zhou, Q., Zahoor, A., & Deng, G. (2023) · Inflammopharmacology · doi:10.1007/s10787-023-01369-9 · Cited by 30
Evolocumab lowers LDL-C safely and effectively when self-administered in the at-home setting
Dent, R. E., Joshi, R., Djedjos, C. S., Legg, J. C., Elliott, M., Geller, M. L., Meyer, D., Somaratne, R. M., Recknor, C. P., & Weiss, R. (2016) · SpringerPlus · doi:10.1186/s40064-016-1892-3 · Cited by 30
“…with PCSK9 inhibition [55–75 % in the evolocumab clinical program (Koren et al. 2014; Raal et al. 2015; Robinson et al. 2014; Stroes et al. 2014; Sabatine et al. 2015; Blom et al. 2014)] presents compelling reason for eligible patients to initiate home-use administration of an injectable…”
InfluentialCariou, B., Leiter, L. A., Müller‐Wieland, D., Bigot, G., Colhoun, H. M., Prato, S. D., Henry, R. R., Tinahones, F. J., Letierce, A., Aurand, L. A., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.01.004 · Cited by 29
“In phase-III clinical studies, alirocumab reduced LDL-C by up to 61% in patients treated with statins [19].”
Ginsberg, H. N., Farnier, M., Robinson, J. G., Cannon, C. P., Sattar, N. A., Baccara‐Dinet, M. T., Letierce, A., Bujas‐Bobanovic, M., Louie, M. J., & Colhoun, H. M. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0439-8 · Cited by 28
Self-citationAre PCSK9 Inhibitors Cost Effective?
Korman, M. J., Retterstøl, K., Kristiansen, I. S., & Wisløff, T. F. (2018) · PharmacoEconomics · doi:10.1007/s40273-018-0671-0 · Cited by 28
Szymański, F. M., Barylski, M., Cybulska, B., Wożakowska−Kapłon, B., Krasiński, Z., Mamcarz, A., Widecka, K., Platek, A. E., Dudek, D., Mickiewicz, A., et al. (2018) · Cardiology Journal · doi:10.5603/cj.2018.0141 · Cited by 32
Ascaso, J. F., Civeira, F., Guijarro, C., López‐Miranda, J., Masana, L., Mostaza, J. M., Pedro‐Botet, J., Pintó, X., & Valdivielso, P. (2019) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2019.06.001 · Cited by 42
Hirai, K., Imamura, S., Hirai, A., Ookawara, S., & Morishita, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103338 · Cited by 29
Emerging Anti-Atherosclerotic Therapies
Gluba-Brzózka, A., Franczyk, B., Rysz-Górzyńska, M., Ławiński, J., & Rysz, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212109 · Cited by 30
“Traditional treatment of atherosclerosis is focused on the reduction in LDL cholesterol [21].”
BackgroundXu, M., Zhu, X., Wu, J., Zhang, Y., Zhao, D., Wang, X., Ding, Y., Cao, Y., Li, C., Hu, W. M., et al. (2022) · BMC Medicine · doi:10.1186/s12916-021-02208-w · Cited by 28
Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease
Hu, J., Lei, H. C., Liu, L., & Xu, D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.812368 · Cited by 28
Suchowerska, A. K., Stokman, G., Palmer, J. T., Coghlan, P. A., Pieterman, E. J., Keijzer, N., Lambert, G. C., Chemello, K., Jaafar, A. K., Parmar, J., et al. (2022) · Journal of Lipid Research · doi:10.1016/j.jlr.2022.100293 · Cited by 28
“The clinical introduction of anti-PCSK9 monoclonal antibodies alirocumab (12) and evolocumab (13) has been successful in lowering plasma LDL-C levels by 50 – 70% and reducing cardiovascular events in patients (13-15).”
BackgroundSafety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
Goodman, S. G., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Harrington, R. A., Jukema, J. W., White, H. D., Zeiher, A. M., et al. (2024) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvae025 · Cited by 29
Self-citationHassan, N. F., El‐Ansary, M. R., Selim, H. M. R. M., Ousman, M. S., Khattab, M. S., El-Ansary, M. R. M., Gad, E. S., Moursi, S. M. M., Gohar, A., & Gowifel, A. M. H. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116929 · Cited by 30
The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice.
Lepor, N. E., & Kereiakes, D. J. (2015) · PubMed · Cited by 40
Self-citationMost Promising Therapies in Interventional Cardiology
Kernéis, M., Nafee, T., Yee, M. K., Kazmi, H. A., Datta, S., Zeitouni, M., Afzal, M. K., Jafarizade, M., Walia, S. S., Qamar, I., et al. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1108-x · Cited by 39
Nanna, M. G., Návar, A. M., Wang, T. Y., Li, S., Virani, S. S., Li, Z., Robinson, J. G., Roger, V. L., Wilson, P. W. F., Goldberg, A. C., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.05.009 · Cited by 29
Self-citationDurairaj, A., Sabates, A., Nieves, J., Moraes, B., & Baum, S. (2017) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-017-0556-0 · Cited by 27
Leiter, L. A., Raal, F. J., Schwartz, G. G., Koenig, W., Ray, K. K., Landmesser, U., Han, J., Conde, L. G., & Wright, R. S. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15650 · Cited by 27
Self-citationTian, W., Cao, H., Li, X., Gong, X., Yu, X., Li, D., Xie, J., Bai, Y., Zhang, D., Li, X., et al. (2025) · CNS Drugs · doi:10.1007/s40263-024-01145-5 · Cited by 28
PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab
Blom, D. J., Dent, R. E., Castro, R. D. C., & Toth, P. P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s102564 · Cited by 27
Alirocumab (Praluent): First in the New Class of PCSK9 Inhibitors.
Manniello, M., & Pisano, M. (2016) · PubMed · Cited by 40
A New Approach to PCSK9 Therapeutics
Wang, N., & Tall, A. R. (2017) · Circulation Research · doi:10.1161/circresaha.117.310610 · Cited by 27
Poller, W. C., Berger, A., Dreger, H., Morgera, S., & Enke-Melzer, K. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.007 · Cited by 27
Page, M. M., & Watts, G. F. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13070 · Cited by 28
“Similarly, a post hoc analysis of a 78-week randomized controlled trial of alirocumab found a 48% reduction in cardiovascular risk in patients randomized to receive alirocumab.(23) This is consistent with a continuous relationship between the degree of lowering of LDL cholesterol and cardiovascular risk reduction attr…”
BackgroundPharmacological Strategies beyond Statins: Ezetimibe and PCSK9 Inhibitors
Choi, J. Y., & Na, J. O. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.2.183 · Cited by 23
van Bruggen, F. H., Nijhuis, G. B. J., Zuidema, S. U., & Luijendijk, H. J. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1787832 · Cited by 28
A Bibliometric Analysis of Familial Hypercholesterolemia From 2011 to 2021
Wei, N., Hu, Y., Liu, G., Li, S., Yuan, G., Shou, X., Zhang, X., Shi, J., & Zhai, H. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101151 · Cited by 29
Management of patients with statin intolerance
Martirossian, A. N., & Goldberg, A. C. (2022) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2022.101714 · Cited by 28
Sobczyk, M., Zheng, J., Smith, G. D., & Gaunt, T. R. (2023) · BMJ Open · doi:10.1136/bmjopen-2023-072087 · Cited by 28
An evaluation of alirocumab for the treatment of hypercholesterolemia
Farnier, M. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1111759 · Cited by 29
Self-citationMasana, L., Ibarretxe, D., & Plana, N. (2016) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.11.016 · Cited by 27
Identifying familial hypercholesterolemia in acute coronary syndrome
Gencer, B., & Nanchen, D. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000311 · Cited by 30
Gulizia, M. M., Colivicchi, F., Ricciardi, G., Giampaoli, S., Maggioni, A. P., Averna, M. R., Graziani, M. S., Ceriotti, F., Mugelli, A., Rossi, F., et al. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux029 · Cited by 27
Self-citationRecent advances in pathogenesis, assessment, and treatment of atherosclerosis
Spence, J. D. (2016) · F1000Research · doi:10.12688/f1000research.8459.1 · Cited by 31
Jaworski, K., Jankowski, P., & KOSIOR, D. A. (2017) · Archives of Medical Science · doi:10.5114/aoms.2017.65239 · Cited by 28
Menzin, J., Aggarwal, J., Boatman, B., Yu, J., Stern, K., Harrison, D. J., & Patel, J. G. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.16414 · Cited by 28
Targeting low‐density lipoprotein cholesterol with PCSK9 inhibitors
Scherer, D. J., Nelson, A. J., Psaltis, P. J., & Nicholls, S. J. (2017) · Internal Medicine Journal · doi:10.1111/imj.13451 · Cited by 29
Chen, K., Wu, Q., Hu, K.-W., Yang, C., Wu, X., Cheung, P., & Williams, K. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310358 · Cited by 27
A Clinical Guide to Combination Lipid-Lowering Therapy
Russell, C. E., Sheth, S., & Jacoby, D. (2018) · Current Atherosclerosis Reports · doi:10.1007/s11883-018-0721-2 · Cited by 27
Okuyama, H., Hamazaki, T., Hama, R., Ogushi, Y., Kobayashi, T., Ohara, N., & Uchino, H. (2018) · Pharmacology · doi:10.1159/000486374 · Cited by 28
A clinically applicable adjuvant for an atherosclerosis vaccine in mice
Kobiyama, K., Vassallo, M., Mitzi, J., Winkels, H., Pei, H., Kimura, T., Miller, J. F., Wolf, D., & Ley, K. F. (2018) · European Journal of Immunology · doi:10.1002/eji.201847584 · Cited by 28
Vrablík, M., Rašlová, K., Vohnout, B., Blaha, V., Satny, M., Kyselák, O., Vaclová, M., Urbánek, R., Mašková, J., Soška, V., et al. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.08.008 · Cited by 28
Wu, C., Xi, C., Tong, J., Zhao, J. Z., Jiang, H., Wang, J., Wang, Y., & Liu, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.06.006 · Cited by 29
Fan, T., Yang, Y., Zeng, Q., Wang, X., Wei, W., Guo, X., Zhao, L., Song, D., Wang, Y., Wang, L., et al. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104994 · Cited by 27
PCSK9 — A Journey to Cardiovascular Outcomes
Burnett, J. R., & Hooper, A. J. (2018) · New England Journal of Medicine · doi:10.1056/nejme1813758 · Cited by 27
γ-secretase inhibition lowers plasma triglyceride-rich lipoproteins by stabilizing the LDL receptor
Kim, K., Goldberg, I. J., Graham, M. J., Sundaram, M., Bertaggia, E., Lee, S. X., Qiang, L., Haeusler, R. A., Metzger, D., Chambon, P., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.010 · Cited by 26
Roth, E. M. (2016) · Future Cardiology · doi:10.2217/fca.15.78 · Cited by 26
Milionis, H. J., Barkas, F., Ntaios, G., Papavasileiou, V., Vemmos, K. N., Michel, P., & Elisaf, M. (2016) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2016.06.023 · Cited by 27
“1%), or with established coronary heart disease (41%) or a coronary heart disease risk equivalent (68%) [8].”
BackgroundMethodResultInfluentialPeng, W., Qiang, F., Peng, W., Qian, Z., Ke, Z., Yi, L., Zhong, J., & Chong-Rong, Q. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.07.239 · Cited by 29
Effects of immunisation against PCSK9 in mice bearing melanoma
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2020) · Archives of Medical Science · doi:10.5114/aoms.2020.91291 · Cited by 26
Cholesterol, carotid artery disease and stroke: what the vascular specialist needs to know
Paraskevas, K. I., Veith, F. J., Eckstein, H., Ricco, J., & Mikhailidis, D. P. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.02.176 · Cited by 27
“All these studies showed that LDL-C lowering with PCSK9 inhibitors was coupled with a significant reduction in MI, stroke and cardiovascular event rates (53-57).”
BackgroundKheirkhah, A., Lamina, C., Rantner, B., Kollerits, B., Stadler, M., Pohlhammer, J., Klein-Weigel, P. F., Fraedrich, G., & Kronenberg, F. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.11.025 · Cited by 28
Lipid-lowering therapy and percutaneous coronary interventions
Koskinas, K. C., Mach, F., & Räber, L. (2021) · EuroIntervention · doi:10.4244/eij-d-20-00999 · Cited by 32
Wang, L., Muthuramu, I., Somanathan, S., Zhang, H., Bell, P. L., He, Z., Yu, H., Zhu, Y., Tretiakova, A. P., & Wilson, J. M. (2021) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2021.04.017 · Cited by 26
Zhang, Y., Suo, Y., Yang, L., Zhang, X., Yu, Q., Zeng, M., Zhang, W., Jiang, X., & Wang, Y. (2022) · Cardiology Research and Practice · doi:10.1155/2022/8729003 · Cited by 27
Metadata
- Authors
- Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., Koren, M. J., Lepor, N. E., Lorenzato, C., Pordy, R., Chaudhari, U., & Kastelein, J. J. P.
- Affiliations
- University of Iowa (US)
- Centre Hospitalier Universitaire de Nantes (FR)
- Université de Lille (FR)
- Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone" di Palermo (IT)
- Amsterdam UMC Location University of Amsterdam (NL)
- Oslo University Hospital (NO)
- University of the Witwatersrand (ZA)
- Jacksonville Center for Clinical Research (US)
- Westside Medical Associates of Los Angeles (US)
- Sanofi (France) (FR)
- Regeneron (United States) (US)
- Sanofi (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-04-16
- Volume
- 372
- Issue
- 16
- Pages
- 1489-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2001328643
- Semantic Scholar
- 942bcfdc93b04ccb90a2d3e1df4c7950a45e92c2
- Cited by
- 2,296
- References
- 35
- Citations by year
- 2026: 67 · 2025: 103 · 2024: 150 · 2023: 141 · 2022: 134 · 2021: 159 · 2020: 165 · 2019: 226 · 2018: 251 · 2017: 339 · 2016: 369 · 2015: 183
- FWCI
- 383.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion, other-oa)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- HAL (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- VBN Forskningsportal (Aalborg Universitet) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- alirocumab, PCSK9 inhibition, LDL cholesterol lowering, statin therapy, major adverse cardiovascular events, cardiovascular risk reduction, monoclonal antibodies, injection site reactions, high-risk patients, lipid-lowering therapy
- MeSH terms
- Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.